May. 12 at 12:13 PM
H.C. Wainwright⬆️
$CLYM's PT to
$20/said: We draw investors' attention to the fact that Climb Bio is poised to have a catalyst-rich year, with multiple clinical milestones slated for achievement with both lead assets from its portfolio.
$RHHBY $VERA BIIB VRTX
H.C. Wainwright added—Enrollment is ongoing in the PrisMN Phase 2 primary membranous nephropathy (pMN) trial of Climb Bio's most advanced asset, budoprutug. PrisMN is a global open-label, dose-ranging Phase 2 study designed to evaluate pharmacodynamics (including B cells, anti-PLA2R, and total immunoglobulin) and preliminary efficacy (including complete and partial remission) in pMN patients with persistent proteinuria despite optimized renin-angiotensin-aldosterone system (RAAS) inhibition, and to identify a dose for Phase 3 development.
Initial data from this trial is anticipated in 4Q26.
We reiterate our Buy rating, while raising our 12-month price target to
$20 from the prior
$15 per share.
